Patrick Serruys
Spencer King
PATRICK SERRUYS, Erasmus University, Rotterdam
COMMENT: SPENCER KING, Piedmont Hospital, Atlanta
REFERENCE: Abstract 2402-3, American College of Cardiology New Orleans
Six-months follow-up of patients receiving a new bioabsorbable drug-eluting stent are favourable, according to Patrick Serruys whose group has been investigating the stent which elutes everolimus in a group of 30 patients. During the ACC Annual Meeting in New Orleans he discussed with Peter Goodwin the potential benefits the new device can bring to coronary patients.
Six-months follow-up of patients receiving a new bioabsorbable drug-eluting stent are favourable, according to Patrick Serruys whose group has been investigating the stent which elutes everolimus in a group of 30 patients. During the ACC Annual Meeting in New Orleans he discussed with Peter Goodwin the potential benefits the new device can bring to coronary patients.
Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.